Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Phase 2
Completed
- Conditions
- Seborrheic Keratosis
- Interventions
- Drug: PEP005 (ingenol mebutate) Gel
- Registration Number
- NCT01214564
- Lead Sponsor
- Peplin
- Brief Summary
This study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with Seborrhoeic Keratosis on non-head locations. The secondary endpoint is to investigate the efficacy of PEP005 Gel, 0.05% when administered for up to three consecutive days to Seborrhoeic Keratosis on non-head locations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 PEP005 (ingenol mebutate) Gel Up to three days of treatment
- Primary Outcome Measures
Name Time Method To evaluate the safety of PEP005 Gel, 0.05% when administered for up to three consecutive days to Seborrhoeic Keratosis on non-head locations. Day 43
- Secondary Outcome Measures
Name Time Method To determine the efficacy of PEP005 Gel, 0.05% when administered for up to three consecutive days to Seborrhoeic Keratosis on non-head locations. Day 43
Trial Locations
- Locations (2)
Specialist Connect
🇦🇺Woolloongabba, Queensland, Australia
Southderm Pty Ltd
🇦🇺Kogarah, New South Wales, Australia